Tokai Pharmaceuticals Presents New Clinical Data For Galeterone Among Patients With Advanced Prostate Cancer At American Society of Clinical Oncology 2014

Published: Jun 02, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer and other hormonally driven cancers, today announced positive interim results from the Phase 2 ARMOR2 study of galeterone (TOK-001) among patients with castration-resistant prostate cancer (CRPC). These data demonstrated clinically meaningful reductions in prostate-specific androgen (PSA) levels, a marker of prostate cancer growth.

Help employers find you! Check out all the jobs and post your resume.

Back to news